📣New eBook: Explore the emerging trends shaping next-gen ADC development: Next-Generation Antibody Drug Conjugates

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimization Campaign - CCS1477

    CellCentric Lead Optimization Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Case Studies
Introducing our Sygnature-FSEC Method
One SEC run, Two fluorescence readouts, highlighting the “Sygnature” peaks with your target protein.
Journal Papers
Multidisciplinary review method for novel target identification and prioritization for neurodegenerative diseases
Tatiana Rosado Rosenstock, Hiromitsu Ohzeki, Shohei Kumagai, Natsuno Suda, Colin Sambrook Smith Abstract Target identification (Target ID) is a foundational, multi-disciplinary…
Blog
Drug Addiction: A Public Health Issue that Refuses to Go Away
Drug addiction remains one of the most persistent and complex public health challenges worldwide. Despite advances in prevention and treatment, drug‑related harm and mortality continue to rise, underscoring the need for deeper biological understanding and more predictive models to support the development of new therapies.
Blog
Substance Use Intoxication (Binge): Insights from Preclinical Models
Focusing on the intoxication phase of addiction, this article examines how behavioral pharmacology models capture reward, reinforcement and binge‑like drug use in preclinical studies.
Blog
Substance Use Withdrawal: How Preclinical Models Inform Treatment Development
Focusing on the withdrawal phase of addiction, this article examines how behavioral pharmacology models assess drug dependence and therapeutic intervention in preclinical studies.
Blog
Craving and Relapse in Addiction: Preclinical Models That Drive Discovery
Focusing on the craving phase of addiction, this article examines how behavioral pharmacology models capture cue‑driven drug seeking and relapse vulnerability.
Blog
Protein and the Planet
Being a biochemist, who is also concerned with sustainability, I was interested to look into…
Blog
Protein and the Planet II – Directed Evolution of Proteins
Following on from our earlier blog, “Protein and…
Pages
SygDesign
Journal Papers
Elucidating the relationship between affinity and potency in the performance of therapeutic IgE
Francesca Marano, Callum McKenzie, James R. Birtley, Sadaf A. Hussain, Olivia Macleod, Alexander Goodacre,…
Blog
High‑Resolution Insight Through Collaboration — Cryo‑EM Structures Supporting the Development of Therapeutic IgE
Therapeutic antibodies of the IgE class are attracting increasing…
Case Studies
X-ray crystallography structure of ERAP1 complexes
We were asked by Greywolf Therapeutics to provide support for an endoplasmic reticulum aminopeptidase-1 (ERAP1)…
Case Studies
Isotopic Labeling of Proteins in a Eukaryotic System
“An Effective Solution for Labelling when Protein Folding is a Challenge” In this case study…
News
Sygnature Discovery collaborates with DaltonTx to advance AI-enabled drug discovery capabilities
We have announced a strategic collaboration with DaltonTx, an AI technology company, to further…
Blog
Enhancing Protein NMR for Drug Discovery – The Role of Deuteration
Structural Biology in Drug Discovery In drug discovery, understanding the structure and dynamics of…
Case Studies
How the Structure of G6b-B was Determined
Our journey started, as it often does, with an X-ray crystallography project which looked…
Pages
QM-Driven drug design with Fragment Molecular Orbital (FMO)
Blog
De-Risking Biotech Fundraising Through Smarter R&D Partnerships: Key Panel Insights
At a recent Sygnature-hosted event in London, we brought together leaders from across biotech,…
Blog
AI Meets Expertise: A Hybrid Approach to Modern Target Identification
This article is adapted from a webinar featuring Daniel Bakowski, PhD (Sygnature Discovery), Saurav…
Technical Notes
Bioinformatics-Driven Cell Model Selection in Drug Discovery
Why model choice has become a data-driven discipline, and how we can support it with platforms such as DepMap, GTEx, and Open Targets
Blog
A Path From Biomarkers to Impact in Drug Discovery
How Translational Science Accelerates Drug Development In discovery and early development, the…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch